ASX set to slide, Wall Street mixed

The Sydney Morning Herald - Oct 13, 2026

The first big batch of summertime profit reports from US companies is making waves on Wall Street after topping analysts’ expectations, but many are cancelling each other out.

Read full article

More News

Oct 13, 2026

I’m sick of immigration being blamed for problems it doesn’t cause

But the resurrection of Pauline Hanson and her ratbag One Nation has changed all that, and now it’s on for young and old.

Oct 13, 2026

Big egg cartel: Major Australian suppliers accused of whipping up higher prices

The competition watchdog has alleged Australia’s largest egg supplier engaged in cartel conduct with a raft of other producers.

Oct 13, 2026

ASX ends flat after slow session on Wall Street; Tech stocks slump, banks jump

The Australian sharemarket was treading water on Tuesday after a sell-off in chipmakers left US stocks wavering ahead of the reporting season.

Oct 13, 2026

Norfolk Metals installs seasoned duo in boardroom overhaul

Norfolk Metals has shuffled its board, appointing veteran Anthony McClure as executive chairman to steer its acquisition of the high-grade Ciclón copper project in Chile.

Oct 13, 2026

Can Adidas really own stripes – and did White Fox copy them?

The German sportswear giant is taking Australian fast fashion outfit White Fox to task over the use of stripes, in a trademark dispute that will test the limits of common-sense and deceptive conduct.

Oct 13, 2026

Demoted for mentioning ‘the glass cliff’? Chris Bradley was just speaking truth

The fact that questioning the glass cliff concept created such a strong kneejerk reaction makes me wonder why challenging the notion should be a punishable crime.

Oct 13, 2026

Orbit sets $12M rare earths spin-off in motion

Orbit Resources has launched a $12 million rare earths float for its Matrix Critical Minerals spin-off, allowing the company to focus on its NSW gold-silver assets.

Oct 13, 2026

NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle

NeuroScientific Biopharmaceuticals has landed key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to final preparations.

Oct 13, 2026

Rewriting Retirement

For those thinking of retirement, this six-part series provides the clarity and confidence to take the next step.

Oct 13, 2026

Don’t blame Ukraine: Prices go up and up, thanks to Trump’s wars

The US president’s battles with trading partners and Iran are responsible for the elevated US inflation rate – not Ukraine’s bombing of Russian oil refineries.